Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
复制标题
DOI：
10.1097/jto.0b013e3181ce684f
复制
发表时间：
2010-03-01
影响因子：
20.4
通讯作者：
Bang, Yung-Jue
中科院分区：
文献类型：
--
作者：
Koh, Youngil;Jang, Bogun;Bang, Yung-Jue
背景资料：我们分析了III类β-微管蛋白（TUBB 3）表达的意义，在根治性切除的非小细胞肺癌作为预后标志物沿着与以前报道的切除修复交叉互补组1（ERCC 1）。排除接受辅助化疗的患者。我们使用免疫组织化学方法一式两份评估组织芯片上TUBB 3和ERCC 1的表达。结果：60%的患者为I期疾病，17%为II期，18%为IIIA期，5%为IIIB期。TUBB 3 H评分显示双峰分布，最小值为4，用作确定TUBB 3阳性的截止值。TUBB 3在60例（44%）患者中表达。TUBB 3阳性表达的患者生存时间短于阴性表达的患者（5年总生存率[OS]为40%对61%; p = 0.005/5年无病生存率为34%对55%; p = 0.024）。ERCC 1表达有延长OS的趋势，但无统计学意义。一项纳入协变量（包括TUBB 3表达、年龄、分期、EGFR突变状态、组织学和ERCC 1表达）的多变量分析显示，TUBB 3是OS的独立不利预后因素。（风险比2.083; p = 0.008）和无复发生存期结论：TUBB 3表达是未接受辅助化疗的治愈性切除非小细胞肺癌患者的独立不良预后标志物。
Background: We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1).Methods: One hundred and thirty-six consecutive patients were included in this retrospective study. Patients who received adjuvant chemotherapy were excluded. We used immunohistochemistry to evaluate TUBB3 and ERCC1 expression on tissue microarray in duplicate. Semiquantitative H score was used for the scoring of tumor staining.Results: Sixty percent of patients had stage I disease, 17% stage II, 18% stage IIIA, and 5% stage IIIB. TUBB3 H score showed bimodal distribution with the minimum at the value of 4, which was used as a cutoff value for determination of TUBB3 positivity. TUBB3 was expressed in 60 patients (44%). Patients with a positive TUBB3 expression survived shorter than did the patients with a negative expression (5-year overall survival [OS] rate was 40% versus 61%; p = 0.005/5-year disease-free survival rate was 34% versus 55%; p = 0.024). ERCC1 expression showed tendency for prolonged OS without reaching statistical significance. A multivariate analysis that incorporated covariates including TUBB3 expression, age, stage, EGFR mutation status, histology, and ERCC1 expression showed that TUBB3 was an independent unfavorable prognostic factor for OS (hazard ratio 2.083; p = 0.008) and relapse free survival (hazard ratio 1.978; p = 0.020).Conclusions: TUBB3 expression is an independent unfavorable prognostic marker in patients with curatively resected non-small cell lung cancer who did not receive adjuvant chemotherapy.